Loading...
•
Sep 30, 2022
Beauty Health Q3 2022 Earnings Report
Net sales beat expectations for the seventh consecutive quarter and the company raised 2022 net sales guidance.
Key Takeaways
BeautyHealth reported strong Q3 2022 financial results, with net sales of $88.8 million, representing a 30% year-over-year growth. The company raised its full year net sales guidance to $360 million to $365 million. Adjusted EBITDA for the quarter was $16.5 million, with a GAAP net income of $0.1 million. However, due to increasing macro pressures, the company revised its full year 2022 adjusted EBITDA guidance to a range of $45.0 to $50.0 million.
Net sales increased by 30% year-over-year to $88.8 million.
Gross margin improved by 174bps year-over-year to 69.3%.
Net income was $0.1 million, compared to a net loss of $215.1 million in Q3 2021.
Adjusted EBITDA was $16.5 million.
Beauty Health
Beauty Health
Beauty Health Revenue by Segment
Beauty Health Revenue by Geographic Location
Revenue by Segment
Delivery Systems Revenue
CapyFin.comConsumables Revenue
CapyFin.comRevenue by Geographic Location
Americas Revenue
CapyFin.comAPAC Revenue
CapyFin.comEMEA Revenue
CapyFin.com Forward Guidance
BeautyHealth increased its fiscal 2022 net sales guidance and now expects net sales in the range of $360.0 million to $365.0 million. The Company also expanded its 2022 outlook for adjusted EBITDA from the prior target of $50.0 million to a range of $45.0 million to $50.0 million.
Positive Outlook
- Net sales guidance increased to $360 million - $365 million.
- Reflects management's confidence in the business.
- Company executes against its growth plan.
Challenges Ahead
- Adjusted EBITDA outlook revised to $45 million - $50 million.
- Continued investment in global expansion.
- Changing macroeconomic pressures.
- Foreign currency exchange headwinds.
- Market closures and restrictions as a result of China’s zero COVID policy.
Revenue & Expenses
Visualization of income flow from segment revenue to net income